Showing 571-580 of 1110 results for "".
Best Practices on Referring Patients With Symptomatic Vitreous Opacities
https://modernod.com/mod-issues/supplements-inserts/best-practices-on-referring-patients-with-symptomatic-vitreous-opacities-1/38428/Treatment of Neurotrophic Keratitis With Topical Insulin
https://modernod.com/topics/corneaanterior-segment/treatment-of-neurotrophic-keratitis-with-topical-insulin/38870/A literature review.Retina in Review
https://modernod.com/topics/retina/retina-in-review/38713/An overview of the latest developments and findings related to the treatment and management of diseases of the posterior segment.Ocular Surface Dryness in Women
https://modernod.com/topics/ocular-surface/ocular-surface-dryness-in-women/38110/An examination of the changing ocular surface through the stages of life.Systemic Comorbidities and Ocular Surface Dryness
https://modernod.com/topics/ocular-surface/systemic-comorbidities-and-ocular-surface-dryness/38260/Taking a thorough systemic case history can prompt eye care providers to screen patients for ocular surface issues.- Neurotech Pharmaceuticals Appoints John Pollack, MD, as Chief Medical Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-john-pollack-md-as-chief-medical-officer/2478549/Neurotech Pharmaceuticals announced that John Pollack, MD, has been appointed to the position of Chief Medical Officer (CMO). Dr. Pollack’s responsibilities will include the execution of clinical studies, patient safety, and the management of Medical Affairs; supporting the required regulatory su
- Optovue Announces Retirement of Industry Veteran John Hawleyhttps://modernod.com/news/optovue-announces-retirement-of-industry-veteran-john-hawley/2480137/Optovue announced the retirement of renowned industry veteran John Hawley, the company’s senior vice president of global sales. Mr. Hawley will retire on July 1, 2018, and remain with Optovue in an advisory role. “For the past 10 years, I have worked side-by-side with John as we built Opto
- Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Boardhttps://modernod.com/news/orasis-announces-appointments-of-richard-l-lindstrom-eric-d-donnenfeld-and-john-berdahl-to-its-scientific-advisory-board/2479644/Orasis Pharmaceuticals announced the appointment of Richard L. Lindstrom, MD, Eric D. Donnenfeld, MD, and John Berdahl, MD, to its scientific advisory board. Dr. Lindstrom, Dr. Donnenfeld, and Dr. Berdahl have joined existing scientific advisory board members Sheri Rowen, MD, and Michael Korenfel
- Alan R. Morse, JD, PhD, Vision and Healthcare Services Innovator, Will Retire As President & CEO of Lighthouse Guildhttps://modernod.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/James M. Dubin, Chairman of the Board of Lighthouse Guild, announced that Alan R. Morse, JD, PhD, will be stepping down later this year as President & CEO of Lighthouse Guild after an extraordinary career of almost 52 years as a leader and innovator in the field
- ViaLase and the John A. Moran Eye Center Partner to Accelerate Glaucoma Research and Innovationhttps://modernod.com/news/vialase-and-the-john-a-moran-eye-center-announce-research-partnership-to-accelerate-glaucoma-research-and-innovation/2482573/ViaLase announced a research partnership with the John A. Moran Eye Center at the University of Utah, home to the Alan S. Crandall Center for Glaucoma Innovation. The collaboration will explore aqueous outflow dynamics of ViaLase’s ViaLase laser procedure, utilizing Moran’s iPerf